Literature DB >> 20627915

Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data.

Nico Derichs1, Javier Sanz, Thomas Von Kanel, Cornelia Stolpe, Antonia Zapf, Burkhard Tümmler, Sabina Gallati, Manfred Ballmann.   

Abstract

BACKGROUND: In questionable cystic fibrosis (CF), mild or monosymptomatic phenotypes frequently cause diagnostic difficulties despite detailed algorithms. CF transmembrane conductance regulator (CFTR)-mediated ion transport can be studied ex vivo in rectal biopsies by intestinal current measurement (ICM).
OBJECTIVES: To describe reference values and validate ICM for the diagnostic classification of questionable CF at all patient ages.
METHODS: ICM was performed in 309 rectal biopsies from 130 infants, children and adults including patients with known pancreatic-insufficient (PI)-CF (n=34), pancreatic-sufficient (PS)-CF (n=7), patients with an unclear diagnosis with mild CF symptoms, intermediate sweat test and/or CFTR mutation screening (n=61) and healthy controls (n=28). ICM was correlated to sweat chloride, extensive CFTR genotype and transcript analysis in the diagnostic group. The results were compared with previous ICM data in subjects with CF, congenital bilateral absence of the vas deferens, heterozygotes and controls.
RESULTS: The cumulative chloride secretory response of DeltaI(sc,carbachol), DeltaI(sc,cAMP/forskolin) and DeltaI(sc,histamine) was the best diagnostic ICM parameter (cut-off 34 muA/cm(2) between patients with known PS-CF and controls), differentiating patients with questionable CF into PS-CF (n=6) and 'CF unlikely' (n=55) groups. Extensive genotype analysis detected two mutations (40% disease-causing) in 100% of individuals classified as PS-CF compared with 1.8% in those classified as 'CF unlikely'.
CONCLUSIONS: This comprehensive investigation of CFTR function and genotype underlines the diagnostic value of ICM, especially for confirmation of CF in the absence of two disease-causing CFTR mutations, exclusion of CF despite intermediate sweat test and age groups unsuitable for nasal potential difference measurements. ICM is an important tool for functional assessment in CFTR mutations of unknown clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627915     DOI: 10.1136/thx.2009.125088

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

Review 1.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

2.  Methods to Study Epithelial Transport Protein Function and Expression in Native Intestine and Caco-2 Cells Grown in 3D.

Authors:  Arivarasu N Anabazhagan; Ishita Chatterjee; Shubha Priyamvada; Anoop Kumar; Sangeeta Tyagi; Seema Saksena; Waddah A Alrefai; Pradeep K Dudeja; Ravinder K Gill
Journal:  J Vis Exp       Date:  2017-03-16       Impact factor: 1.355

3.  Current clinical opinion on CFTR dysfunction and patient risk of pancreatitis: diagnostic and therapeutic considerations.

Authors:  Madhura Y Phadke; Zachary M Sellers
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2022-06-02       Impact factor: 4.095

4.  Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis.

Authors:  Marisa Sousa; Maria F Servidoni; Adriana M Vinagre; Anabela S Ramalho; Luciana C Bonadia; Verónica Felício; Maria A Ribeiro; Inna Uliyakina; Fernando A Marson; Arthur Kmit; Silvia R Cardoso; José D Ribeiro; Carmen S Bertuzzo; Lisete Sousa; Karl Kunzelmann; Antônio F Ribeiro; Margarida D Amaral
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

5.  The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients.

Authors:  Eva K Roth; Stephanie Hirtz; Julia Duerr; Daniel Wenning; Irmgard Eichler; Hans H Seydewitz; Margarida D Amaral; Marcus A Mall
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

6.  Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis.

Authors:  Claudio Sorio; Mario Buffelli; Chiara Angiari; Michele Ettorre; Jan Johansson; Marzia Vezzalini; Laura Viviani; Mario Ricciardi; Genny Verzè; Baroukh Maurice Assael; Paola Melotti
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

Review 7.  Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis.

Authors:  Simon Y Graeber; Constanze Vitzthum; Marcus A Mall
Journal:  J Pers Med       Date:  2021-05-08

8.  Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.

Authors:  Elena Kondratyeva; Tatyana Bukharova; Anna Efremova; Yuliya Melyanovskaya; Natalia Bulatenko; Ksenia Davydenko; Alexandra Filatova; Mikhail Skoblov; Stanislav Krasovsky; Nika Petrova; Alexander Polyakov; Tagui Adyan; Elena Amelina; Vera Shadrina; Elena Zhekaite; Aysa Zodbinova; Alexander Chernyak; Rena Zinchenko; Sergei Kutsev; Dmitry Goldshtein
Journal:  Genes (Basel)       Date:  2021-05-28       Impact factor: 4.096

9.  Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility.

Authors:  Maria F Servidoni; Marisa Sousa; Adriana M Vinagre; Silvia R Cardoso; Maria A Ribeiro; Luciana R Meirelles; Rita B de Carvalho; Karl Kunzelmann; Antônio F Ribeiro; José D Ribeiro; Margarida D Amaral
Journal:  BMC Gastroenterol       Date:  2013-05-20       Impact factor: 3.067

10.  Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function.

Authors:  John P Clancy; Rhonda D Szczesniak; Melissa A Ashlock; Sarah E Ernst; Lijuan Fan; Douglas B Hornick; Philip H Karp; Umer Khan; James Lymp; Alicia J Ostmann; Amir Rezayat; Timothy D Starner; Shajan P Sugandha; Hongtao Sun; Nancy Quinney; Scott H Donaldson; Steven M Rowe; Sherif E Gabriel
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.